Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Clinical Trial of Stereotactic Ablative Radiotherapy for Metastatic Lymphadenopathy

NCT02803151 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT02803151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02803151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Clinical Trial of Stereotactic Ablative Radiotherapy for Metastatic Lymphadenopathy
Lead sponsor
National Taiwan University Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
May 31, 2016
Completion date
May 31, 2021
Enrollment
59 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis of malignant neoplasm to lymph node